All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia

Pediatr Blood Cancer. 2008 Jul;51(1):133-5. doi: 10.1002/pbc.21529.

Abstract

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML). Treatment of pediatric APL is based on the combination of all-trans-retinoic acid (ATRA), an anthracycline and cytosine arabinoside. Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excellent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy. There is little data on combination therapy with ATRA and ATO in pediatric APL. We present a case of an adolescent male with APL who was treated using ATRA and ATO without conventional chemotherapy agents.

MeSH terms

  • Adolescent
  • Arsenic Trioxide
  • Arsenicals / therapeutic use*
  • Disease-Free Survival
  • Dysplastic Nevus Syndrome
  • Humans
  • Leukemia, Promyelocytic, Acute / complications
  • Leukemia, Promyelocytic, Acute / diagnosis*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Oxides / therapeutic use*
  • Tretinoin / therapeutic use*

Substances

  • Arsenicals
  • Oxides
  • Tretinoin
  • Arsenic Trioxide